Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)

BACKGROUND: Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory therapies may allow the dose of immunosuppressive drugs to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Popp, Felix C, Fillenberg, Barbara, Eggenhofer, Elke, Renner, Philipp, Dillmann, Johannes, Benseler, Volker, Schnitzbauer, Andreas A, Hutchinson, James, Deans, Robert, Ladenheim, Deborah, Graveen, Cheryl A, Zeman, Florian, Koller, Michael, Hoogduijn, Martin J, Geissler, Edward K, Schlitt, Hans J, Dahlke, Marc H
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2011
Konular:
Protocol
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3166276/
https://ncbi.nlm.nih.gov/pubmed/21798013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-9-124
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller